News Highlights

Check this page for recent news from Appili Therapeutics.

Members of the media can contact us here, or for general inquiries, contact us here.

November 19, 2021
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
November 12, 2021
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
November 12, 2021
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
October 14, 2021
Appili Therapeutics Announces Closing of Public Offering of $7,000,220
October 7, 2021
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering